ejpmr, 2024, 11(7), 163-170

SJIF Impact Factor 7.065

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

BEYOND THE SURFACE: A DEEP DIVE INTO CTD AND ECTD PROTOCOL DYNAMICS

Kadam Shruti Sunil[1]*, Rajpure Pranjal Madhukar[2], Devade Omkar Ashok[3] and V. K. Redasani[4]

[1,2]Student, YSPM'S YTC Yashoda Technical Campus Wadhe, Satara.
[3]Department of Pharmacology, YSPM"s YTC, Satara, Maharashtra, 415011.
[4]Director of YSPM"s YTC, Satara, Maharashtra, 415011.

***Corresponding Author: Kadam Shruti Sunil**

Student, YSPM'S YTC Yashoda Technical Campus Wadhe, Satara.

Article Received on 15/05/2024 **Article Revised on 05/06/2024** **Article Accepted on 26/06/2024**

ABSTRACT

The Common Technical Document (CTD) was developed to establish a standardized format across Europe, the USA, and Japan for the technical documentation required in applications for human pharmaceutical product registration. It comprises five main modules: Module 1 covers administrative and prescribing information, Module 2 includes overviews and summaries of Modules 3–5, Module 3 focuses on quality with pharmaceutical documentation, Module 4 contains non-clinical reports on pharmacology and toxicology, and Module 5 encompasses clinical study reports from clinical trials. Detailed guidelines outline the content for each module, and adherence to the CTD format is now mandatory for the majority of submission dossiers.

KEYWORDS: CTD, eCTD, Modules, Summary, Regulatory.

BACKGROUND

Prior to the introduction of the Common Technical Document (CTD) in 2002, the European Union (EU), the United States (USA), and Japan each had their own distinct regulatory frameworks and dossier submission formats for obtaining marketing approval for new drugs or modifications to existing licenses. In Japan, the GAIYO was responsible for organizing and presenting technical material, which typically required written summaries. Meanwhile, Europe mandated expert reports and tabulated summaries. The Food and Drug Administration (FDA) in the United States provided guidelines on the structure and contents of the New Drug Application (NDA). However, due to variations in criteria and forms across countries and regions within the EU, the submission process was time-consuming and involved repetitive procedures.[1]

In 2000, delegates from the European Medicines Agency (EMA), the US FDA, and Japan's Ministry of Health, Labour, and Welfare collaborated to establish guidelines outlining the structure and content of a dossier for new medicine registration applications across their regions. These guidelines, developed within the framework of The International Conference on Harmonisation (ICH), are now part of the ICH guidelines. The primary goal of the Common Technical Document (CTD) was to streamline the documentation process, reducing time and resources required for pharmaceutical registration applications while facilitating electronic submissions. Furthermore, adopting a standardized document format with common elements aimed to simplify regulatory reviews, applicant communications, and the exchange of regulatory information among authorities.[2]

INTRODUCTION

The Common Technical Documents (CTD) represent a standardized set of requirements for medicine registration and design, applicable across Europe, the United States (US), and Japan. Developed collaboratively by the European Medicines Agency (EMA), the Food and Drug Administration (FDA), and the Ministry of Health, Labor, and Welfare in Japan (MHLW), it serves as an internationally accepted format for submitting applications for new medications to regulatory bodies in participating countries. Maintained by the International Council on Harmonization (ICH), the CTD ensures consistency in technical requirements for pharmacological approval for human use, and it is universally recognized for organizing submissions to regulatory authorities worldwide.[3] The maintenance of the Common Technical Document (CTD) falls under the purview of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).[4]

Over the last 15 to 20 years, the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) has worked to create a standardized dossier for drug

applications known as the Common Technical Document (CTD) for Pharmaceutical Registration.[5]

Recent advancements in technology and science have transformed the landscape of drug development and marketing. Regulatory affairs now utilize various online platforms to store crucial data such as eCTD and CTD, exemplified by Pharma. READY: Freyr Global regulatory solution. Notable regulatory bodies like the FDA, TGA, CDSCO, and EMEA have streamlined processes for the pharmaceutical sector, ensuring compliance with global standards for manufacturing chemicals, biological medicines, medical equipment, traditional herbal products, and cosmetics for both humans and animals. This stringent regulatory framework has been meticulously refined over time, resulting in the establishment of robust systems for the production and distribution of safe, effective, and high-quality medicines.[1]

Common Technical Document

The CTD format dossier reduces the time and resources required to issue different MA applications for different regulatory authorities and facilitates the preparation of electronic documentation. As a result, the regulatory analysis and the communication between health authorities and the applicant have been facilitated by standardizing a document that contains common elements. Additionally, from this standardized format, it was also possible to simplify the exchange of regulatory information between the different authorities.[3]

Objectives of CTD

The primary goal of CTD is to streamline the application compilation process, reducing time and resource expenditure. It aims to enable electronic submission preparation and facilitate simultaneous submissions across three regions. Additionally, CTD aims to enhance the exchange of regulatory information, expediting the availability of new medicines.[3]

POINT TO BE CONSIDERING WHEN PREPARING THE CTD

Organizing a drug application in CTD format is no more challenging than a standard NDA, especially with available guidance. However, there are occasions where considering both the presentation "art" and scientific aspects can offer significant advantages. Throughout the CTD, information display should prioritize clarity and transparency to aid reviewers in quickly grasping the application's contents. Despite the often substantial size of CTD applications, there are opportunities for creativity, storytelling, and constructing cohesive arguments to aid regulatory comprehension. The modular format, with varying levels of detail, allows for both an overall view and access to supporting details. Due to the complexity and size of CTD applications, meticulous cross-referencing within and between modules is crucial. While each module serves a specific function, Modules 2 and 3 offer key areas for informative and creative content, facilitating data integration, presentation of strengths and limitations, and providing reviewers with a comprehensive understanding. Emphasizing clarity, avoiding exaggerations, openly discussing negative findings and shortcomings, and substantiating claims are vital for a favorable reception of the CTD application. Remember, undocumented claims are mere rumors.[13]



Fig No: 1- CTD Triangle.[6]

ORGANISATION OF CTD

The Common Technical Document is organized into five modules.

The CTD dossier comprises five main sections (as shown in fig 1):

1. Module 1: Administrative particulars and prescription information
2. Module 2: Summaries of the Common Technical Document
3. Module 3: Quality documentation pertaining to pharmaceutical elements
4. Module 4: Non-clinical reports covering toxicology and pharmacology
5. Module 5: Clinical study reports encompassing clinical trials

Module 1 is tailored to specific regions, while Modules 2, 3, 4, and 5 are designed to be universally applicable. Adherence to this guideline should guarantee that these four modules are presented in a manner acceptable to regulatory authorities.[7]

Module 1: Administrative Information and Prescribing Information

This module should contain documents specific to each region; for example, application forms or the proposed label for use in the region. The content and format of this module can be specified by the relevant regulatory authorities.[7]

Module 2: Common Technical Document Summaries
Module 2 should begin with a general introduction to the pharmaceutical, including its pharmacologic class, mode of action, and proposed clinical use. In general, the Introduction should not exceed one page.Module 2 should contain 7 sections in the following order:

- CTD Table of Contents
- CTD Introduction
- Quality Overall Summary
- Nonclinical Overview
- Clinical Overview
- Nonclinical Written and Tabulated Summaries
- Clinical Summary

The organisation of these summaries is described in Guidelines for M4Q, M4S, and M4E.

Module 3: Quality
Information on Quality should be presented in the structured format described in Guideline M4Q.

Module 4: Nonclinical Study Reports
The nonclinical study reports should be presented in the order described in Guideline M4S.

Module 5: Clinical Study Reports
The human study reports and related information should be presented in the order described in Guideline M4E.
The overall organisation of the Common Technical Document is presented on the following pages.[8]

Module 1: Administrative and Prescribing Information
1.0 Cover Letter
1.1 Detailed Table of Contents
1.2 Application Form
1.3 Product Information
1.3.1 Summary of Product Characteristics (SPC), Labeling, and Packaging
1.3.2 Mock-Up Samples
1.3.3 Specimen Packaging
1.3.4 Feedback from Target Patient Group Consultation
1.3.5 Existing SPCs Approved in Member States
1.3.6 Braille Labeling
1.4 Expert Information
1.5 Requirements for Various Application Types
1.6 Environmental Risk Assessment
1.7 Orphan Market Exclusivity Details
1.8 Pharmacovigilance Information
1.9 Clinical Trial Data
1.10 Pediatric Information.[7],[9]

Module 2: CTD summary
2.1 Comprehensive Table of Contents
2.2 General Introduction to the Pharmaceutical: Including Pharmacology Class, Mode of Action, and Proposed Clinical Use
2.3 Quality Overall Summary
2.4 Non-clinical Overview
2.4.1 General Aspects
2.4.2 Content and Structural Format
2.5 Clinical Overview
2.5.1 Product Development and Content Rationale
2.5.2 Biopharmaceutics Overview
2.5.3 Clinical Pharmacology Overview
2.5.4 Efficacy Overview
2.5.5 Safety Overview
2.5.6 Conclusions on Benefits and Risks
2.5.7 References from Literature
2.6 Non-clinical Written and Tabulated Summaries
2.6.1 Pharmacology Summary
2.6.2 Pharmacokinetics Summary
2.6.3 Toxicology Summary
2.7 Clinical Summary
2.7.1 Biopharmaceutic Studies and Associated Analytical Methods
2.7.2 Studies in Clinical Pharmacology
2.7.3 Efficacy in Clinical Studies
2.7.4 Safety in Clinical Studies
2.7.5 References from Literature
2.7.6 Synopses of Individual Studies.[9],[10]

Module 3: Quality
3.1 Table of Contents
3.2 Body of Data
3.2. S Drug Substance
3.2. S.1 General Information
3.2. S.1.1 Nomenclature
3.2. S.1.2 Structure
3.2. S.1.3 General Properties
3.2. S.2 Manufacture
3.2. S.2.1 Manufacturer Details
3.2. S.2.2 Description of Manufacturing Process and Process Controls
3.2. S.2.3 Control of Materials
3.2. S.2.4 Controls of Critical Steps and Intermediates
3.2. S.2.5 Process Validation and /or Evaluation
3.2. S.2.6 Manufacturing Process Development
3.2. S.3 Characterization
3.2. S.3.1 Elucidation of structure and other Characteristics
3.2. S.3.2 Impurities
3.2. S.4 Control of Drug Substance
3.2. S.4.1 Specification of Drug Substance
3.2. S.4.2 Analytical Procedures
3.2. S.4.3 Validation of Analytical Procedures
3.2. S.4.4 Batch Analyses
3.2. S.4.5 Justification of Specification
3.2. S.5 Reference Standards or Materials
3.2. S.6 Container Closure System
3.2. S.7 Stability
3.2. S.7.1 Stability Summary and Conclusions
3.2. S.7.2 Post-approval Stability Protocol and Stability Commitment
3.2. S.7.3 Stability Data
3.2. P Drug Product
3.2. P.1 Description and Composition of the Drug Product
3.2. P.2 Pharmaceutical Development
3.2. P.2.1 Components of Drug Product
3.2. P.2.2 Drug Product

3.2. P.2.3 Manufacturing Process Development
3.2. P.2.4 Container Closure System
3.2. P.2.5 Microbiological Characteristics
3.2. P.2.6 Compatibility
3.2. P.3 Manufacturing
3.2. P.3.1 Manufacturer Details
3.2. P.3.2 Batch Formulation
3.2. P.3.3 Description of Manufacturing Process and Controls
3.2. P.3.4 Management of Critical Steps and Intermediates
3.2. P.3.5 Process Validation and Evaluation
3.2. P.4 Excipient Control
3.2. P.3.2.P.4.1 Specifications
3.2. P.4.2 Analytical Methods
3.2. P.4.3 Validation of Analytical Methods
3.2. P.4.4 Rationale for Specifications
3.2. P.4.5 Excipients from Human or Animal Sources
3.2. P.4.6 New Excipients Management
3.2. P. Control of Finished Product
3.2. P.5.1 Product Specifications
3.2. P.5.2 Analytical Techniques
3.2. P.5.3 Validation of Analytical Techniques
3.2. P.5.4 Batch Analysis
3.2. P.5.5 Impurity Characterization
3.2. P.5.6 Rationale for Specifications
3.2. P.6 Reference Materials
3.2. P.7 Closure System
3.2. P.8 Stability
3.2. P.8.1 Summary and Conclusions on Stability
3.2. P.8.2 Post-approval Stability Protocol and Commitments
3.2. P.8.3 Stability Data
3.2. A Supplementary Information
3.2. A.1 Facility and Equipment Details
3.2. A.2 Evaluation of Contaminants Risks
3.2. A.3 Novel Excipients Information
3.2. R Regional Specifics / Requirements
3.2. R.1 Process Validation and or Evaluation
3.2. R.2 Medical Device
3.2. R.3 Restricted part of DMF
3.2. R.4 Medicinal products containing or using in the manufacturing process materials of
animal and / or human origin.
3.3 List of Literature References.[10]

Module 4: Non-clinical Study Reports
4.1 Contents Overview
4.2 Study Findings
4.2.1 Pharmacology
4.2.1.1 Primary Pharmacodynamic Effects
4.2.1.2 Secondary Pharmacodynamic Effects
4.2.1.3 Safety Considerations in Pharmacology
4.2.1.4 Interactions in Pharmacodynamics
4.2.2 Pharmacokinetics
4.2.2.1 Methodology and Validation Reports
4.2.2.2 Absorption Patterns
4.2.2.3 Distribution Profiles
4.2.2.4 Metabolic Pathways
4.2.2.5 Excretion Rates
4.2.2.6 Pharmacokinetic Interactions
4.2.2.7 Additional Pharmacokinetic Investigations
4.2.3 Toxicology
4.2.3.1 Single-Dose Toxicity Assessments
4.2.3.2 Repeated-Dose Toxicity Evaluations
4.2.3.3 Genotoxicity Studies
4.2.3.4 Carcinogenicity Investigations
4.2.3.5 Reproductive and Developmental Toxicity Assessments
4.2.3.6 Local Tolerance Examinations
4.2.3.7 Further Toxicity Explorations
4.3 References.[11]

Module 5: Clinical Study Reports
5.1 Contents Overview
5.2 Comprehensive Tabular Presentation of Clinical Studies
5.3 Documented Clinical Investigations
5.3.1 Bioavailability Studies
5.3.1.1 Bioavailability (BA) Study Reports
5.3.1.2 Comparative BA and Bioequivalence Study Reports
5.3.1.3 In-vitro In-vivo Correlation Study Reports
5.3.1.4 Bioanalytical and Analytical Method Reports
5.3.2 Pharmacokinetic Studies
5.3.2.1 Plasma Protein Binding Study Reports
5.3.2.2 Hepatic Metabolism and Drug Interaction Study Reports
5.3.2.3 Studies Utilizing Human Biomaterials Reports
5.3.3 PK and Tolerability Assessments
5.3.3.1 Healthy Subject PK and Initial Tolerability Study Reports
5.3.3.2 Patient PK and Initial Tolerability Study Reports
5.3.3.3 Intrinsic Factor PK Study Reports
5.3.3.4 Extrinsic Factor PK Study Reports
5.3.3.5 Population PK Study Reports
5.3.4 Pharmacodynamics and PK/PD Assessments
5.3.4.1 Healthy Subject PD and PK/PD Study Reports
5.3.4.2 Patient PD and PK/PD Study Reports
5.3.5 Clinical Study Analysis
5.3.5.1 Controlled Clinical Study Reports
5.3.5.2 Uncontrolled Clinical Study Reports
5.3.5.3 Multi-study Data Analysis Reports
5.3.5.4 Miscellaneous Clinical Study Reports
5.3.6 Post-Marketing Experience Reports
5.3.7 Individual Patient Data Documentation
5.4 Key Literature References List.[12]

Advantages Of CTD

1. The important purpose of using a only one application is to make it easier to review each application and avoid other important documents or reviews. Missions of this collected data can cause approvals to be delayed unnecessarily.
2. This is a common format for technical documentation. Significant savings in time and resources. Required to fill out a personnel application In addition to drug registration, Preparing e-filing has become easier

3. A standard document with common elements. It can be used to facilitate regulatory reviews and communication with the applicant.
4. Implementing a CTD reduces the time and resources required for companies to prepare international registration applications.[13]

Benefits of CTD

1. Training Rules Documentation: CTD simplifies the process of preparing training rules documents, ensuring they are comprehensive and ready for submission during the Investigational New Drug (IND) period. This not only saves time but also ensures compliance with regulatory requirements.
2. Project Management and Data Standardization: Through standardization, CTD enables more efficient project management and data handling. By establishing uniform formats and protocols, it becomes easier to track progress, collaborate across teams, and maintain data integrity. This streamlining enhances overall productivity and reduces the risk of errors or inconsistencies.
3. Lifecycle Management Simplification: CTD simplifies the management of a drug's lifecycle by providing a structured framework for organizing and updating documentation throughout the development process. This ensures that information remains organized, accessible, and up-to-date, facilitating smoother transitions between different stages of development and regulatory review.
4. Support for Drug Development Initiatives: Beyond its organizational benefits, CTD provides valuable support for various drug development initiatives. By facilitating the compilation and presentation of data in a standardized format, it helps researchers and developers communicate effectively with regulatory agencies, investors, and other stakeholders. This support can accelerate the development timeline and increase the likelihood of successful regulatory approval.[14]

Electronic common technical document (eCTD)

The eCTD serves as the electronic counterpart of the traditional CTD, offering a standardized interface for industry to agency transmission of regulatory data, facilitating submission creation, review, lifecycle management, and archival. Agreed upon by major global agencies, it comprises a structured set of folders containing PDFs and SAS files, typically on a CD/DVD or through agency web portals. At its core lies an XML backbone delineating submission structure, file links, and metadata like checksum information. Essentially, it's a digital compilation of common technical documents submitted electronically to regulatory bodies, mandated by European legislation. While it streamlines submissions for applications, supplements, reports, and more, adherence to its format remains a significant challenge for applicants and promoters, as deviations may lead to rejection.

The electronic Common Technical Document (eCTD) represents a significant advancement in regulatory document management, particularly in the pharmaceutical industry. It essentially digitizes the entire process of document submission, review, and archival, replacing the traditional paper-based system with a streamlined electronic framework.

At its core, eCTD employs a structured format based on Extensible Markup Language (XML), which allows for the systematic organization of data and metadata. Each submission package is composed of multiple XML files, including the backbone file, module files, and regional administrative files. These files contain not only the documents themselves but also critical metadata such as document type, version, and relationships between documents.[14]

One of the key advantages of eCTD is its strict adherence to standardized schemas and formats. This ensures consistency and compatibility across submissions, making it easier for regulatory agencies to review and process documents. Additionally, eCTD facilitates the inclusion of hyperlinks and bookmarks within documents, enabling easy navigation and reference.

Moreover, eCTD mandates that all submissions, including initial applications and subsequent updates, be in electronic format. This requirement eliminates the need for paper submissions, reducing the risk of errors and delays associated with manual processing.

From a regulatory standpoint, eCTD serves as a centralized platform for the exchange of information between pharmaceutical companies and regulatory agencies. It enables seamless communication and collaboration, allowing stakeholders to share data, track submissions, and respond to inquiries more efficiently.

Overall, the adoption of eCTD represents a significant step forward in modernizing regulatory processes within the pharmaceutical industry. By digitizing document management and standardizing submission formats, eCTD improves efficiency, accuracy, and transparency in the regulatory review process.[15]

Modules in eCTD

1. Region-specific information: This module contains details specific to the regulatory requirements of different regions or countries where the submission is intended for approval.
2. Summary documents: These documents provide an overview of the submission, summarizing key information for regulatory authorities.
3. Quality-related information: This module includes data and documentation related to the quality aspects of the product, such as manufacturing processes, specifications, and stability studies.

4. Reports on animal trials: It comprises reports and data from preclinical studies conducted on animals to assess the safety and efficacy of the product.
5. Clinical study reports (CSRs) for human trials: This module contains comprehensive reports on the clinical trials conducted in humans, including study protocols, results, and analyses, essential for evaluating the safety and efficacy of the product for regulatory approval.[16]

Advantages of using eCTD

1. Established Standards: eCTD is built on recognized standards that have remained largely unchanged over time, providing a stable foundation for integrating International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) requirements. This ensures consistency and reliability in regulatory submissions.
2. Enhanced Regulatory Tools: Regulatory tools used for reviewing submissions have undergone upgrades, resulting in improved performance and efficiency. This allows for smoother interactions between regulatory authorities and applicants, streamlining the review process.
3. Uniform Format: eCTD follows a common format for submissions in both the United States and Europe, with only minor modifications required for aspects such as Module 1 and STF (Study Tagging File) acceptance. This simplifies the preparation and submission process for applicants operating in multiple regions.
4. Comprehensive Submission History: The eCTD life cycle offers detailed submission histories, enabling easy access to past submissions and facilitating knowledge transfer for products. This comprehensive documentation enhances regulatory compliance and transparency
5. Consolidated Format: The consolidated format of eCTD submissions provides transparency by organizing all relevant information into a structured and standardized format. This makes it easier for regulatory authorities to access and review the submitted data, reducing the likelihood of errors or omissions.
6. Simplified Publishing: Publishing submissions with eCTD is straightforward, thanks to the use of simple and intuitive tools. This simplification minimizes the complexity associated with preparing and submitting regulatory documents, saving time and resources for applicants.
7. Ease of Collaboration: Updates and changes can be easily shared with multiple local affiliates involved in the submission process, fostering collaboration and ensuring consistency across regions. This facilitates efficient communication and coordination within multinational organizations.
8. No Viewer Required: Unlike traditional paper-based submissions, eCTD does not require a separate viewer during the submission process. This simplifies the submission workflow and reduces the need for additional software or tools, enhancing accessibility and usability.
9. Affordable Implementation: Implementing eCTD is cost-effective compared to traditional submission methods. The standardized format, streamlined processes, and reduced need for physical materials contribute to lower overall costs for applicants, making eCTD a practical choice for regulatory submissions.[17].[18]

eCTD challenges

With the mandatory adoption of the eCTD format in key markets, companies face the challenge of establishing a cohesive environment to streamline the lifecycle of various submission types. This involves efficiently managing the exhaustive process of gathering, validating, approving, and documenting new drug and medical device applications. Such an environment must facilitate seamless collaboration between different stakeholders, ensure compliance with regulatory requirements, and enable efficient tracking and retrieval of submission documents. Additionally, companies need robust systems in place to handle version control, maintain data integrity, and address any technical complexities associated with the eCTD format. Overall, establishing a unified environment is essential for optimizing the submission process and maintaining regulatory compliance in the ever-evolving landscape of drug and medical device regulations.[19]

Other eCTD challenges

- Cutting-edge technology and experienced staff are necessary.
- Standardization is required due to content not being uniformly formatted.
- Variations exist in hyperlinking, bookmarking, and PDF versions across regions.
- Last-minute changes are challenging to implement.
- Employee turnover leads to loss of product knowledge.
- Local affiliates have restricted access for customization.
- Validation rules vary regionally.
- Baseline submissions are expensive and offer limited value.
- Managing the life cycle is difficult.
- Authentication methods differ between regions.
- A unified approach to dossier drafting is needed.[18][19][20]

Risks involved in eCTD publishing

As regulatory departments worldwide transition from paper-based to eCTD submissions, they face a myriad of challenges. These challenges can range from technical issues to logistical hurdles, and they can significantly impact the efficiency and success of submission processes. However, by implementing strategic measures, regulatory teams can mitigate these challenges and ensure smoother eCTD publishing experiences.

One common challenge is the complexity of eCTD formatting and submission requirements. Navigating the intricacies of eCTD structure and specifications can be daunting, especially for teams with limited experience or resources. To address this challenge, investing in comprehensive training and resources for staff members involved in eCTD publishing can enhance their proficiency and confidence in meeting submission requirements.

Another challenge is ensuring consistency and accuracy across multiple documents and submissions. With the volume of documents involved in regulatory submissions, maintaining uniformity in formatting, terminology, and content can be challenging. Implementing standardized templates, style guides, and quality control processes can help ensure consistency and accuracy throughout the publishing process.[20]

Additionally, managing timelines and deadlines poses a significant challenge for regulatory departments. Coordinating the efforts of various stakeholders, including internal teams and external partners, while adhering to regulatory timelines requires effective communication and project management strategies. Establishing clear timelines, milestones, and escalation procedures can help streamline the publishing process and minimize delays.

Furthermore, maintaining compliance with evolving regulatory requirements presents an ongoing challenge for regulatory departments. Regulatory guidelines and requirements are subject to change, necessitating continuous monitoring and adaptation of submission processes. Regularly updating internal procedures and staying informed about regulatory updates can help ensure ongoing compliance and minimize the risk of submission rejections or delays.

Overall, by addressing these common challenges through proactive measures such as training, standardization, effective communication, and compliance monitoring, regulatory departments can optimize their eCTD publishing processes and enhance the likelihood of submission success.[21]

REFERENCES

1. Guideline ICH. Organisation of the Common Technical Document for the Registration of Pharmaceuticals for Human Use M4. Geneva: ICH., 2004.
2. Jordan D. An overview of the Common Technical Document (CTD) regulatory dossier. Medical Writing, Jun 1, 2014; 23(2): 101-5.
3. Vaibhav Subhash Janjal. GSC Biological and Pharmaceutical Sciences, 2021; 16(03): 200–221. Recent drug regulatory affair and CTD module progress review for submission of pharmaceuticals product.
4. Bhalodiya H. A., Boda J. M., Shah J. S., Patel P. B., Vaghela J. P. The Common Technical Document (CTD): Taking Indian NDA process towards Globalization. International Journal of Pharmaceutical Sciences Review and Research (IJPSRR), July–Aug, 2011; 9(2): 181-187.
5. Roth I R; "Preparing the Common Technical Document for Registration of Pharmaceuticals for Human Use (CTD) – Insight and Recommendations"; Drug Information Journal, 2008; 42: 149-159.
6. ICH. CTD Triangle [Internet], 2010; 1.
7. K. P. R. Chowdary, K. Ravi Shankar .World Journal of Pharmacy and Pharmaceutical Sciences. CTD – A CRITICAL DOCUMENT FOR DOSSIER SUBMISSIONS: AN OVERVIEW, 2015; 4(11).
8. ICH M4 Guideline: General Questions & AnswersDocument (R3) [2004 Jun].
9. Naishi Kirtikumar, Dr. Dilip Maheshwari. Documentation requirements for generic drug application to be marketed in India- a Review. Journal of Pharmaceutical Science and Bioscientific Research (JPSBR)., 2014; 4(4): 237-242.
10. "ICH Harmonised Tripartite Guideline: The Common Technical Document For The Registration Of Pharmaceuticals For Human Use: Quality – M4Q(R1): Quality Overall Summary Of Module 2 & Module 3 -Quality".
11. "ICH Harmonised Tripartite Guideline: The Common Technical Document For The Registration Of Pharmaceuticals For Human Use: Safety – M4S (R2): Nonclinical Overview And Nonclinical Summaries Of Module 2 &Organisation Of Module 4".
12. "ICH Harmonised Tripartite Guideline: The Common Technical Document For The Registration Of Pharmaceuticals For Human Use: Efficacy – M4E (R1) Clinical Overview And Clinical Summary Of Module 2 & Module 5 - Clinical Study Reports".
13. Mahaparale S, Desai B. Role and overview of drug regulatory affairs in pharmaceutical industry with implementation of CTD and ECTD. Sonali al World J Pharm Res [Internet], 2018; 7.
14. Foster M H; "Managing the Drug Development Process with eCTD Tools: Advantages of Preparing Submissions Electronically".
15. Suchanek A, Ostermann H. The Electronic Common Technical Document (eCTD): An International Pro/Con Analysis of the Pharmaceutical Product Electronic Submission Process. Drug Inf J., Jan. 2012; 46(1): 124–39.
16. Cartwright AC. The electronic common technical document: From design to submission. Int J Pharm Med., 2006; 20(3): 149–58.
17. The ASEAN common technical dossier (ACTD) for the registration of pharmaceuticals for human use; September 2002 from Wikipedia.
18. Nisar Ahammad, Nagarjuna Reddy. Journal of Drug Delivery & Therapeutics, 2019; 9(4-s): 673-679.

Challenges Faced During eCTD and CTD Filling Procedures for USFDA and Canada.
19. Patel Veer J., Patel Dasharath M.International Journal of Drug Regulatory Affairs. Year., 2021; 9(1.A) comprehensive review on registration requirements for drug approval in India, South Africa and US.
20. Sahitya, K. et al. 'Regulatory Pathway for Registration and Approval of Indian Drug Products in Overseas Market.' Journal of Pharmaceutical Science and Research. [Internet], 2020; 12(0975-1459): 1150-1161. Available from: www. Just. Pharma info. In.
21. Rasheed, A., and Dixit, M. 'Regulatory Requirements and Different Pathways for Registration of Drug Products in the United Kingdom.' Scholars Research Library. [Internet], 2015; (0975-5071): 188-195.